Alzheimer’s disease is marked by a high density of senile plaques, whose principal component is the 42-residue b-amyloid peptide. In my lab, several B-amyloid peptide vaccines have been synthesized and formulated with a human-compatible alum ajuvant. Presently, Alzheimer’s vaccines are being tested in chemical trials. We hope that our continued basic research on Alzheimer’s disease will lead to practical breakthroughs for treating this presently incurable and socially devastating human malady.
Raso, V. (2000) Intracellular targeting using bispecific antibodies. Meth. Mol. Med. 25, 37-50.
Lynch, G.W., Sloane, A.J., Raso, V., Lai, A. & A.L. Cunningham (1999) Direct evidence for native CD4 oligomers in lymphoid and monocytoid cells. Eur. J. Immunol. 29, 2590-2602.
Raso, V., Brown, M., McGrath, J., Liu, S. & W.F. Stafford (1997) Antibodies capable of releasing diphtheria toxin in response to the low pH found in endosomes. J. Biol. Chem. 272, 27618-27622.
Raso, V., Brown, M. & J. McGrath (1997) Intracellular targeting with low pH-triggered bispecific antibodies. J. Biol. Chem. 272, 27623-27628.
Raso, V. (1994) Immunotargeting intracellular compartments. Analyt.l Biochem. 222, 297-304.